Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy.
Globoid cell leukodystrophy (GLD, Krabbe disease), is an autosomal recessive, neurodegenerative disease caused by the deficiency of the lysosomal enzyme galactocerebrosidase (GALC). In the absence of GALC, the toxic metabolite psychosine accumulates in the brain and causes the death of the myelin-producing cells, oligodendrocytes. Currently, the only therapy for GLD is hematopoietic stem cell transplantation using bone marrow (BMT) or umbilical cord blood. However, this is only partially effective. Previous studies have shown that enzyme replacement therapy (ERT) provides some therapeutic benefit in the murine model of GLD, the Twitcher mouse. Experiments have also shown that two disparate therapies can produce synergistic effects when combined. The current study tests the hypothesis that BMT will increase the therapeutic effects of ERT when these two treatments are combined. Twitcher mice were treated with either ERT alone or both ERT and BMT during the first 2-4 days of life. Recombinant enzyme was delivered by intracerebroventricular (ICV) and intrathecal (IT) injections. Twitcher mice receiving ERT had supraphysiological levels of GALC activity in the brain 24h after injection. At 36 days of age, ERT-treated Twitcher mice had reduced psychosine levels, reduced neuroinflammation, improved motor function, and increased lifespan. Twitcher mice receiving both ERT and BMT had significantly increased lifespan, improved motor function, reduced psychosine levels, and reduced neuroinflammation in certain areas of the brain compared to untreated or ERT-treated Twitcher mice. Together, these results indicate that BMT enhances the efficacy of ERT in GLD.
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Elizabeth Y
EY
Qin
Jacqueline A
JA
Hawkins-Salsbury
Xuntian
X
Jiang
Adarsh S
AS
Reddy
Nuri B
NB
Farber
Daniel S
DS
Ory
Mark S
MS
Sands
D000818:Animals; D016026:Bone Marrow Transplantation; D001921:Brain / Q000378:metabolism / Q000473:pathology; D002490:Central Nervous System / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy; D005698:Galactosylceramidase / Q000008:administration & dosage / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D007965:Leukodystrophy, Globoid Cell / Q000401:mortality / Q000628:therapy*; D051379:Mice; D018345:Mice, Knockout; D011609:Psychosine / Q000378:metabolism; D019172:Transplantation Conditioning
D011609:Psychosine; D005698:Galactosylceramidase